Requires HHS to review brand-name drug prices and label them "excessive" when they fail tests (an international-price test using five reference countries or a secondary factor-based test). When a drug is found excessively priced, the Secretary can cancel government-granted exclusivities, authorize open non-exclusive licenses so others can make the drug, accelerate review of generic/biosimilar applications, and pursue monetary recovery from the manufacturer. The bill also mandates public transparency (a searchable database and annual reports), annual manufacturer reporting on prices/revenues/R&D, civil penalties for false or late reports (funding NIH grants), and a prohibition on anticompetitive conduct that would block open licensing.